2. Academic Validation
  3. HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance

HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance

  • Leukemia. 2010 Oct;24(10):1807-9. doi: 10.1038/leu.2010.169.
H Luo,  H Quan,  C Xie,  Y Xu,  L Fu,  L Lou
PMID: 20703259 DOI: 10.1038/leu.2010.169
Figures
Products